Published: 15 June 2026. The English Chronicle Desk. The English Chronicle Online.
The British high street has experienced another dramatic twist in its long retail history today. Australia’s prominent pharmaceutical giant Sigma Healthcare has officially abandoned its ambitious pursuit of Boots. This sudden decision brings a swift end to a potential ten-billion-dollar takeover deal. The massive transaction would have been worth approximately seven billion pounds to the current owners. Sigma leadership announced on Monday that the proposed acquisition simply failed their core strategic goals. They stated that buying the vast British pharmacy network did not meet capital investment objectives.
The high street giant currently operates around one thousand eight hundred stores across the United Kingdom. Last week the Financial Times reported that early stage acquisition talks were actively taking place. Financial markets reacted immediately and positively to the news of the discussions being terminated. Shares in the Australian wholesaling and retailing group jumped six percent on Monday morning. Investors appeared to have breathed a collective sigh of relief following the official announcement. This rapid stock rally suggests shareholders prefer management to focus on their current domestic opportunities. They would rather avoid another incredibly complex and transformational deal of this massive scale.
Sigma management released a comprehensive statement detailing their future corporate path moving forward. The company remains entirely confident in its well-established and highly successful domestic growth strategy. Their primary focus will continue to be centered firmly on the competitive Australian market. However, the firm noted that overseas expansion still remains an essential pillar of growth. A successful acquisition would have significantly expanded Sigma’s overall footprint in the United Kingdom. This move would have followed their recent acquisition of a controlling stake in Greenlight Healthcare. That smaller UK pharmacy chain deal was successfully completed just during the previous month.
The Australian business has been undergoing its own massive corporate restructuring over recent months. Last year the company finalised a historic merger with the popular brand Chemist Warehouse. This monumental deal effectively created a massive thirty-billion-dollar pharmacy and retail corporate group. The initial value of the merger was eight billion dollars in December 2023. Since that landmark announcement, Sigma shares have incredibly increased more than threefold in total value.
This unexpected withdrawal extends a lengthy period of deep uncertainty for the British brand. The iconic one-hundred-and-seventy-seven-year-old high street chemist was originally put up for sale in 2022. Several global suitors have expressed varying degrees of interest during this prolonged period. The Canadian branch of the prominent and billionaire Weston family was also recently interested. This wealthy family already owns the massive Loblaws grocery chain in their home country. They also successfully operate the highly popular Shoppers Drug Mart pharmacy brand across Canada.
This latest development effectively dashes hopes that Boots could rejoin London’s struggling stock market. Recent corporate appointments had strongly fed growing expectations of a highly anticipated public listing. Alex Baldock, the accomplished former boss of Currys, was reportedly appointed as chief executive. This significant leadership move led many financial analysts to believe a float was coming.
The famous company was originally founded in Nottingham in 1849 by John Boot. Over the past twenty years, the historic business has changed hands several times. A major merger with Alliance Unichem initially took place in the year 2006. The combined corporate entity was then swiftly taken private by equity firm KKR. This massive private equity takeover was completed in a highly publicised 2007 deal. American giant Walgreens then purchased an initial forty-five percent stake in the year 2012. Walgreens fully completed its total takeover of the business at the end of 2014.
Today the massive retail business employs about fifty-one thousand people across the nation. This large workforce includes around six thousand dedicated employees based at the corporate headquarters. This sprawling main office is located in Beeston, just south-west of historic Nottingham.
Despite the corporate uncertainty, the high street retailer has recently posted very strong results. Boots reported last week that its overall revenues rose over three percent annually. Total revenue reached seven and a half billion pounds for the financial year. This successful period ran up to the end of August in 2025. Pre-tax profits surged impressively by twenty-five percent during this exact same timeframe. Final pre-tax profits reached an excellent total of three hundred and thirty-seven million pounds. The company stated that exceptional demand for weight-loss jabs boosted their overall profits. A renewed and highly successful focus on beauty products also drove this substantial growth.
A future sale to the Canadian Weston family remains a distinct structural possibility. This potential deal would see the prominent billionaires reappear in the British retail sector. The family previously sold the luxury department store Selfridges for four billion pounds. That major transaction was finalised in 2022 before this current pharmacy interest emerged. High street analysts will be watching the next corporate moves with intense interest. For now, the famous British chemist remains under its current American ownership structure. Customers can expect business as usual across the vast network of local stores. The search for a definitive long-term solution for the historic brand continues unabated.

























































































